Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 692342

Drug Profile

GSK 692342

Alternative Names: 692342; GSK M72; GSK-692342; M72/AS01E; Mtb72F/AS02A

Latest Information Update: 05 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 05 Feb 2018 GSK 692342 is still in phase II trials for Tuberculosis in Kenya, South Africa and Zambia (NCT01755598)
  • 21 Jul 2015 Phase-II development is ongoing in Belgium, Gambia, India, Philippines, Switzerland and South Africa
  • 01 Jun 2015 GlaxoSmithKline completes a phase-II trial in Tuberculosis in India (NCT01262976)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top